奥比努图库单抗
滤泡性淋巴瘤
医学
美罗华
肿瘤科
化疗
淋巴瘤
危险系数
不利影响
内科学
CD20
外科
置信区间
作者
Robert Marcus,Andrew Davies,Kiyoshi Ando,Wolfram Klapper,Stephen Opat,Carolyn Owen,Elizabeth H. Phillips,Randeep Sangha,Rudolf Schlag,John F. Seymour,William Townsend,Marek Trněný,Michael Wenger,Günter Fingerle‐Rowson,Kaspar Rufibach,Tom Moore,Michael Herold,Wolfgang Hiddemann
标识
DOI：10.1056/nejmoa1614598
摘要
Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Criminology34
GingerF
Adc
奶油桃子
无极微光
sswbzh
VDC
药药
null
完美芷雪
mammer
小葡萄icon
8R60d8
劉浏琉
專注完美近乎苛求
Rondab
ellen
andrele
MchemG
斯文的山兰
遇上就这样吧
小蘑菇
斯文败类
NexusExplorer
皖公网安备34019202002308
